Investors in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) had a good week, as its shares rose 3.1% to close at US$259 following the release of its first-quarter results. It looks like the results were pretty good overall. While revenues of US$594m were in line with analyst predictions, statutory losses were much smaller than expected, with Alnylam Pharmaceuticals losing US$0.44 per share. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.NasdaqGS:ALNY Earnings and Revenue Growth May 4th 2025

Taking into account the latest results, the most recent consensus for Alnylam Pharmaceuticals from 31 analysts is for revenues of US$2.91b in 2025. If met, it would imply a huge 24% increase on its revenue over the past 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 45% to US$1.14. Before this latest report, the consensus had been expecting revenues of US$2.89b and US$1.76 per share in losses. Although the revenue estimates have not really changed Alnylam Pharmaceuticals'future looks a little different to the past, with a very promising decrease in the loss per share forecasts in particular.

Check out our latest analysis for Alnylam Pharmaceuticals

The average price target held steady at US$321, seeming to indicate that business is performing in line with expectations. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Alnylam Pharmaceuticals, with the most bullish analyst valuing it at US$500 and the most bearish at US$212 per share. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We can infer from the latest estimates that forecasts expect a continuation of Alnylam Pharmaceuticals'historical trends, as the 33% annualised revenue growth to the end of 2025 is roughly in line with the 37% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 18% per year. So it's pretty clear that Alnylam Pharmaceuticals is forecast to grow substantially faster than its industry.

Story Continues

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Alnylam Pharmaceuticals going out to 2027, and you can see them free on our platform here..

And what about risks? Every company has them, and we've spotted  1 warning sign for Alnylam Pharmaceuticals  you should know about.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments